The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000496314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/03/2026
Date registered
Help: Date registered
22/04/2026
Date last updated
Help: Date last updated
22/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Robot-Assisted Sacrocolpopexy Using Autologous Posterior Rectus Sheath Restore Vaginal Support: The RESTORE Study
Scientific title
Evaluating the use of Robot-Assisted Sacrocolpopexy Using Autologous Posterior Rectus Sheath Restore Vaginal Support on pelvic organ positioning in adults with pelvic organ prolapse: The RESTORE Study
Additional trial identifiers [1] 316757 0
None
Universal Trial Number (UTN)
Trial acronym
The RESTORE Study
Related trial records

Health condition
Health condition(s) studied:
Pelvic organ prolapse 341038 0
Condition category
Condition code
Reproductive Health and Childbirth 337179 337179 0 0
Other reproductive health and childbirth disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Robot-assisted sacrocolpopexy using posterior rectus sheath (PRS) a novel alternative autologous graft for the treatment of pelvic organ prolapse. Harvested from local abdominal fascial tissue, PRS can be harvested from the same operative field used for sacrocolpopexy, eliminating the need for a separate thigh incision. The procedure will be completed in a single surgical session lasting approximately 90 minutes. All participating surgeons are suitably trained and proficient in performing POP-Q examination, robotic sacral colpopexy and posterior rectus sheath harvesting. The participating surgeons will receive standardised training in harvesting and PRS and placement of the graft onto the vagina. This training will involve direct observation of one case performed by the principal investigator. Following the observed case, the participating surgeon will perform three cases under the direct supervision of the principal investigator.
Intervention code [1] 333443 0
Treatment: Surgery
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344698 0
The mean position of the vaginal apex (POP-Q point C) at 1-year following surgery, compared with baseline
Timepoint [1] 344698 0
Baseline (at enrollment) and 1 year post enrolment.
Primary outcome [2] 344791 0
The standard deviation of the position of the vaginal apex (POP-Q point C) at 1-year following surgery, compared with baseline
Timepoint [2] 344791 0
Baseline (at enrollment) and 1-year post enrolment
Primary outcome [3] 344792 0
The distribution of point C of the position of the vaginal apex (POP-Q point C) at 1-year following surgery, compared with baseline
Timepoint [3] 344792 0
Baseline (at enrollment) and 1-year post enrolment
Secondary outcome [1] 458911 0
Any change in the vaginal apex (POP-Q point-C) positioned at least 2cm above the hymen at maximal Valsalva 1-year following surgery.
Timepoint [1] 458911 0
1 year post enrolment
Secondary outcome [2] 458913 0
The position of the apical vaginal compartment as defined by point-C (POP-Q) at maximal Valsalva at baseline and 6-months and 1-year
Timepoint [2] 458913 0
Baseline (at enrollment), 6 months and 1 year post enrolment
Secondary outcome [3] 458914 0
Baseline (at enrollment), 6-month and 1-year scores of POP-Q measurements in vaginal compartments other than the apical compartment at maximal Valsalva. Assessed together as a composite secondary outcome.
Timepoint [3] 458914 0
Baseline (at enrollment), 6-months and 1-year post enrolment
Secondary outcome [4] 458915 0
Baseline (at enrollment), 6-month and 1-year scores of the Australian Pelvic Floor Questionnaire (APFQ)
Timepoint [4] 458915 0
Baseline (at enrollment), 6-months and 1 year post enrolment
Secondary outcome [5] 458916 0
Overall APFQ score provides an overall picture on how patients are progressing post surgery in their every day quality of life. The individual domain scores allows for a more in-depth analysis of the severity of symptoms.
Timepoint [5] 458916 0
Baseline (at enrollment), 6months and 1-year post enrolment
Secondary outcome [6] 458917 0
Subjective cure as defined by responses to the 28th question (Do you feel a sensation of tissue or a lump or bulging in your vagina?) of the APFQ.
Timepoint [6] 458917 0
6-months and 1-year post enrolment.
Secondary outcome [7] 458918 0
Treatment satisfaction scores assessed by using the Short Assessment of Patient Satisfaction (SAPS) tool regarding Overall total SAPS score.
Timepoint [7] 458918 0
6-months and 1-year post enrolment
Secondary outcome [8] 458919 0
Intraoperative complications
Timepoint [8] 458919 0
Day of surgery
Secondary outcome [9] 458920 0
Numeric rating scale (NRS) for donor site pain assessment
Timepoint [9] 458920 0
Day of discharge, post-operative follow up (4 weeks), 6-months and 1-year post-enrolment
Secondary outcome [10] 458922 0
Prevalence of repeat prolapse surgery post operative.
Timepoint [10] 458922 0
6 months follow-up and 1-year follow-up post operative.
Secondary outcome [11] 458923 0
Details of concomitant surgery. These are the names of various urogynaecology surgeries performed previously such as pelvic Organ Prolapse surgery (POP) Stress Urinary Incontinence surgery (SUI) Hysterectomy Urge Urinary Incontinence/Over Active Bladder surgery (UUI/OAB)
Timepoint [11] 458923 0
Intra-operative
Secondary outcome [12] 458924 0
Prevalence of adverse event: o Urinary tract injury o Hematoma o Haemorrhage o Infection (including urinary tract infections) o Posterior Rectus Sheath donor site morbidity o Recurrence of prolapse within 1-year o Graft exposure o Other (i.e., pain etc)
Timepoint [12] 458924 0
Day of discharge, post-operative follow-up (4 weeks), 6 months and 12 months follow up post enrolment.
Secondary outcome [13] 459171 0
Australian Pelvic Floor Questionnaire (APFQ) bladder function domain
Timepoint [13] 459171 0
Baseline, 6months and 1-year post enrolment
Secondary outcome [14] 459174 0
APFQ Prolapse symptoms domain
Timepoint [14] 459174 0
Baseline, 6-month and 1-year post enrolment
Secondary outcome [15] 459175 0
APFQ Sexual function domain
Timepoint [15] 459175 0
Baseline, 6-month and 1-year post enrolment.
Secondary outcome [16] 459176 0
APFQ Bowel function
Timepoint [16] 459176 0
Baseline, 6-month and 1-year post enrolment
Secondary outcome [17] 459177 0
Short Assessment of Patient Satisfaction Question (SAPS) 1 “How satisfied are you with the effect of your treatment?” (Very satisfied (rating of 0) through to very dissatisfied (rating of 4)
Timepoint [17] 459177 0
6-month and 1-year post enrolment
Secondary outcome [18] 459226 0
Prevalence of pessary insertion post-operative.
Timepoint [18] 459226 0
Post-operative follow up (4weeks), 6 months follow-up and 1-year follow-up post operative
Secondary outcome [19] 459616 0
Post-operative complications
Timepoint [19] 459616 0
4 weeks, 6months and 1 year post enrolment

Eligibility
Key inclusion criteria
• Women 18 years old or older.
• Consecutive women with greater than or stage 2 vaginal vault or uterine prolapse
• Women that are able to comprehend and complete the study material
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
• Women undergoing prolapse surgery who are unwilling or unable to participate in the study
• Women who are unwilling or unable to give competent informed consent or unable to complete study questionnaires
• Uterine abnormalities that exclude participation for subjects undergoing a sub-total hysterectomy are:
o Abnormal endometrial thickness or sampling
o Current or recent cervical dysplasia
o Abnormal menstrual bleeding
o Post-menopausal bleeding
• High risk for endometrial cancer
o Hereditary Non-Polyposis Colorectal Cancer (Lynch Syndrome), BRCA 1&2
o Tamoxifen therapy
• High risk for general anaesthesia and/or laparoscopic surgery

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
This exploratory study is intended to report the width of the 95% confidence interval of the mean of the primary outcome, POP-Q Point C, at 12- months, compared with baseline. We believe that 34 participants is logistically feasible. Allowing for 15% attrition, 34/0.85 = 40 patients would be required in order to complete the study with 34 patients. Categorical variables such as success will be reported as percentages. Continuous or dimensional variables such as POP-Q measurements and APFQ scores will be described using means and standard deviations, or medians and interquartile ranges (the difference between the 25th and 75th percentiles) if distributions are observed to be skewed. Relevant graphs of POP-Q point-C characteristics such as histograms and boxplots will be generated.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321355 0
Hospital
Name [1] 321355 0
Epworth HealthCare
Country [1] 321355 0
Australia
Primary sponsor type
Hospital
Name
Epworth HealthCare
Address
Country
Australia
Secondary sponsor category [1] 324096 0
None
Name [1] 324096 0
Address [1] 324096 0
Country [1] 324096 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319890 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 319890 0
Ethics committee country [1] 319890 0
Australia
Date submitted for ethics approval [1] 319890 0
30/09/2025
Approval date [1] 319890 0
06/03/2026
Ethics approval number [1] 319890 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148742 0
A/Prof Marcus Carey
Address 148742 0
Epworth HealthCare, Level 5, Suite 5.2, 124 Grey St East Melbourne, 3002, Victoria
Country 148742 0
Australia
Phone 148742 0
+61 3 8386 7977
Fax 148742 0
Email 148742 0
Contact person for public queries
Name 148743 0
Jayne Damm
Address 148743 0
Epworth HealthCare, Ground Floor, 185-187 Hoddle St, Richmond 3121, Victoria
Country 148743 0
Australia
Phone 148743 0
+61 3 9936 8068
Fax 148743 0
Email 148743 0
Contact person for scientific queries
Name 148744 0
Marcus Carey
Address 148744 0
Epworth HealthCare, Level 5, Suite 5.2, 124 Grey St East Melbourne, Victoria, 3002
Country 148744 0
Australia
Phone 148744 0
+61 3 8386 7977
Fax 148744 0
Email 148744 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.